Abstract Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular
transition into S phase and are important for the initiation, growth and survival of many …

The cyclin-dependent kinase (CDK) 4/6 inhibitors belong to a new class of drugs that
interrupt proliferation of malignant cells by inhibiting progression through the cell cycle …

The development and approval of cyclin-dependent kinase (CDK) 4 and 6 inhibitors for
hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative …

High-fidelity DNA replication is critical for the faithful transmission of genetic information to
daughter cells. Following genotoxic stress, specialized DNA damage tolerance pathways …

Cancer is characterized by uncontrolled tumour cell proliferation resulting from aberrant
activity of various cell cycle proteins. Therefore, cell cycle regulators are considered …

We report the discovery of sulanemadlin (ALRN-6924), the first cell-permeating, stabilized α-
helical peptide to enter clinical trials. ALRN-6924 is a “stapled peptide” that mimics the N …

Biochemical and genetic characterization of D-type cyclins, their cyclin D–dependent
kinases (CDK4 and CDK6), and the polypeptide CDK4/6 inhibitor p16INK4 over two …

Cancer represents a pathological manifestation of uncontrolled cell division; therefore, it has
long been anticipated that our understanding of the basic principles of cell cycle control …

Summary Background Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of
cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of growth-inhibitory …

Small-molecule inhibitors of the CDK4/6 cell-cycle kinases have shown clinical efficacy in
estrogen receptor (ER)-positive metastatic breast cancer, although their cytostatic effects are …